Habit training versus habit training with direct visual biofeedback in adults with chronic constipation: A randomized controlled trial.


Journal

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611

Informations de publication

Date de publication:
11 2023
Historique:
revised: 08 06 2023
received: 21 02 2023
accepted: 30 06 2023
medline: 27 11 2023
pubmed: 9 9 2023
entrez: 9 9 2023
Statut: ppublish

Résumé

The aim was to determine whether specialist-led habit training using Habit Training with Biofeedback (HTBF) is more effective than specialist-led habit training alone (HT) for chronic constipation and whether outcomes of interventions are improved by stratification to HTBF or HT based on diagnosis (functional defaecation disorder vs. no functional defaecation disorder) by radio-physiological investigations (INVEST). This was a parallel three-arm randomized single-blinded controlled trial, permitting two randomized comparisons: HTBF versus HT alone; INVEST- versus no-INVEST-guided intervention. The inclusion criteria were age 18-70 years; attending specialist hospitals in England; self-reported constipation for >6 months; refractory to basic treatment. The main exclusions were secondary constipation and previous experience of the trial interventions. The primary outcome was the mean change in Patient Assessment of Constipation Quality of Life score at 6 months on intention to treat. The secondary outcomes were validated disease-specific and psychological questionnaires and cost-effectiveness (based on EQ-5D-5L). In all, 182 patients were randomized 3:3:2 (target 384): HT n = 68; HTBF n = 68; INVEST-guided treatment n = 46. All interventions had similar reductions (improvement) in the primary outcome at 6 months (approximately -0.8 points of a 4-point scale) with no statistically significant difference between HT and HTBF (-0.03 points; 95% CI -0.33 to 0.27; P = 0.85) or INVEST versus no-INVEST (0.22; -0.11 to 0.55; P = 0.19). Secondary outcomes showed a benefit for all interventions with no evidence of greater cost-effectiveness of HTBF or INVEST compared with HT. The results of the study at 6 months were inconclusive. However, with the caveat of under-recruitment and further attrition at 6 months, a simple, cheaper approach to intervention may be as clinically effective and more cost-effective than more complex and invasive approaches.

Identifiants

pubmed: 37684725
doi: 10.1111/codi.16738
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2243-2256

Subventions

Organisme : National Institute for Health and Care Research
ID : RP-PG-0612-20001

Informations de copyright

© 2023 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

Références

Cook IJ, Talley NJ, Benninga MA, Rao SS, Scott SM. Chronic constipation: overview and challenges. Neurogastroenterol Motil. 2009;21(Suppl 2):1-8.
Wald A, Scarpignato C, Mueller-Lissner S, Kamm MA, Hinkel U, Helfrich I, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28:917-930.
Chiotakakou-Faliakou E, Kamm MA, Roy AJ, Storrie JB, Turner IC. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. Gut. 1998;42:517-521.
Bleijenberg G, Kuijpers HC. Biofeedback treatment of constipation: a comparison of two methods. Am J Gastroenterol. 1994;89:1021-1026.
Koutsomanis D, Lennard-Jones JE, Roy AJ, Kamm MA. Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation. Gut. 1995;37:95-99.
Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428-441.
Heymen S, Wexner SD, Vickers D, Nogueras JJ, Weiss EG, Pikarsky AJ. Prospective, randomized trial comparing four biofeedback techniques for patients with constipation. Dis Colon Rectum. 1999;42:1388-1393.
Glia A, Gylin M, Gullberg K, Lindberg G. Biofeedback retraining in patients with functional constipation and paradoxical puborectalis contraction: comparison of anal manometry and sphincter electromyography for feedback. Dis Colon Rectum. 1997;40:889-895.
Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657-664.
Rao SS. Biofeedback therapy for constipation in adults. Best Pract Res Clin Gastroenterol. 2011;25:159-166.
Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218-238.
Enck P, Van der Voort IR, Klosterhalfen S. Biofeedback therapy in fecal incontinence and constipation. Neurogastroenterol Motil. 2009;21:1133-1141.
Etherson KJ, Horrocks EJ, Scott SM, Knowles CH, Yiannakou Y. A national biofeedback practitioners service evaluation: focus on chronic idiopathic constipation. Frontline Gastroenterol. 2017;8:62-67.
Rao SS, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5:331-338.
Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005;129:86-97.
Simon MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2009;34:273-277.
Farid M, El Monem HA, Omar W, El Nakeeb A, Fikry A, Youssef T, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Color Dis. 2009;24:115-120.
Lehur PA, Stuto A, Fantoli M, Villani RD, Queralto M, Lazorthes F, et al. Outcomes of stapled transanal rectal resection vs. biofeedback for the treatment of outlet obstruction associated with rectal intussusception and rectocele: a multicenter, randomized, controlled trial. Dis Colon Rectum. 2008;51:1611-1618.
Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database Syst Rev. 2014;3:CD008486.
Knowles CH, Booth L, Brown SR, Cross S, Eldridge S, Emmett C, et al. Non-drug therapies for the management of chronic constipation in adults: the CapaCiTY research programme including three RCTs. Programme Grants for Applied Research. Southampton (UK). 2021;9:1-134.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344-2354.
Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527-536.
NICE (National Institute for Health and Care Excellence). Constipation in children and young Adults: diagnosis and managment. Clinical Guideline 99. London: NICE; 2010.
Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5-S21.
American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S1-S4.
Norton C, Emmanuel A, Stevens N, Scott M, Grossi U, Bannister S, et al. Habit training versus habit training with direct visual biofeedback in adults with chronic constipation: study protocol for a randomised controlled trial. Trials. 2017;18:139.
Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40:540-551.
Cowlam S, Milburn S, McColl E, Yiannakou Y. Preliminary validation of the PAC-QoL questionnaire for chronic idiopathic constipation in patients in the UK. Gastroenterology. 2007;132:A442.
Khan U, Mason J, Hungin AP, Varma JS, Yiannakou Y. Temporary sacral nerve stimulation (SNS) in neuropathic constipation. Gut. 2011;60:A67-A68.
Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil. 2010;22:e54-e63.
NHS Business Services Authority. NHS Prescription Cost Analysis data. 2019. [cited 2020 Jul 03] https://www.nhsba.nhs.uk/prescription-data/dispensing-data/prescription-cost-analaysis-pca-data
Office for National Statistics. Average weekly earnings in Great Britain: February 2020. [cited 2020 Jul 03] http://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentand employeetypes/bulletins/averageweeklyearningsgreatbritain
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708-715.
Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139.
Kahan BC, Morris TP. Analysis of multicentre trials with continuous outcomes: when and how should we account for Centre effects? Stat Med. 2013;32:1136-1149.
Grossi U, Heinrich H, Di Tanna GL, Taylor SA, Vollebregt PF, Knowles CH, et al. Systematic characterization of defecographic abnormalities in a consecutive series of 827 patients with chronic constipation. Dis Colon Rectum. 2021;64:1385-1397.
Hu WH, Li JH, Chan AO, Wong NY, Wong SH, Hui WM. Biofeedback is an effective treatment for functional constipation: a randomized controlled study. Gastroenterology. 2006;130:A287.
Cotelle O, Cargill G, Marty MM, Bueno L, Cappelletti MC, Colangeli-Hagege H, et al. A concomitant treatment by CO2-releasing suppositories improves the results of anorectal biofeedback training in patients with dyschezia: results of a randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2014;57:781-789.
Grossi U, Carrington EV, Bharucha AE, Horrocks EJ, Scott SM, Knowles CH. Diagnostic accuracy study of anorectal manometry for diagnosis of dyssynergic defecation. Gut. 2015;65:447-455.
Palit S, Thin N, Knowles CH, Lunniss PJ, Bharucha AE, Scott SM. Diagnostic disagreement between tests of evacuatory function: a prospective study of 100 constipated patients. Neurogastroenterol Motil. 2016;28:1589-1598.
Rao SSC, Go JT, Valestin J, Schneider J. Home biofeedback for the treatment of dyssynergic defecation: does it improve quality of life and is it cost-effective? Am J Gastroenterol. 2019;114:938-944.
Everitt HA, Landau S, O'Reilly G, Sibelli A, Hughes S, Windgassen S, et al. Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial. Lancet Gastroenterol Hepatol. 2019;4:863-872.
Everitt HA, Landau S, O'Reilly G, Sibelli A, Hughes S, Windgassen S, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019;68:1613-1623.

Auteurs

Christine Norton (C)

Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK.

Sybil Bannister (S)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Lesley Booth (L)

Bowel Research UK, Registered Charity, London, UK.

Steve R Brown (SR)

Sheffield Teaching Hospitals NHS Trust & University of Sheffield, Sheffield, UK.

Samantha Cross (S)

Department Biostatistics and Health Informatics, Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK.

Sandra Eldridge (S)

Pragmatic Clinical Trials Unit, Institute of Population Health Sciences, Barts and the London School of Medicine and dentistry, Queen Mary University of London, London, UK.

Christopher Emmett (C)

County Durham and Darlington NHS Foundation Trust, Durham, UK.

Ugo Grossi (U)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Mary Jordan (M)

Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Warwick, UK.

Jon Lacy-Colson (J)

Royal Shrewsbury Hospital, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.

James Mason (J)

Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Warwick, UK.

John McLaughlin (J)

Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Sciences Centre, Manchester, UK.

Rona Moss-Morris (R)

Department of Psychology, Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK.

S Mark Scott (SM)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Natasha Stevens (N)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Shiva Taheri (S)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Stuart A Taylor (SA)

Centre for Medical Imaging, University College London, London, UK.

Yan Yiannakou (Y)

County Durham and Darlington NHS Foundation Trust, Durham, UK.

Charles H Knowles (CH)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH